Centiva Capital’s Royalty Pharma RPRX Stock Holding History

Centiva Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,860	Closed	-$201K	–	2060
2024 Q4	$201K	Buy	+7,860	New	+$208K	﹤0.01%	1367
2021 Q1	–	Hold	0	–	–	–	637

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Centiva Capital's RPRX Position: Q1 2025 in Review

Centiva Capital sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 7,860 shares — an estimated $201K sold.

Centiva Capital first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $201K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

Centiva Capital reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
Centiva Capital sold 7,860 Royalty Pharma shares in Q1 2025, an estimated $201K.
Centiva Capital first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
Centiva Capital's Royalty Pharma position peaked at $201K in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.